Updated on 17 July 2013
Mr James Pusey is the new president and general manager contract research organization (CRO) WuXiPRA, China
Singapore: China-based WuXiPRA, a contract research organization (CRO), has appointed Mr James Pusey, as president and general manager. Dr Pusey has more than 25 years of experience in medicine, international clinical trial management, CRO services, and global pharmaceutical sales, marketing, and clinical operations.
Prior to joining WuXiPRA, Dr Pusey was founding CEO of Theorem Clinical Research, where he served as president and chief executive officer, executive chairman, and board director from 2009 through 2013. Previously, Dr Pusey served as senior vice president and general manager of global clinical development at MDS Pharma Services. During his tenure at both of these global CROs, he successfully reorganized and developed their Asian businesses for significant growth.
Dr Pusey has also served as president and chief executive officer of Orthologic, a biotechnology company based in Phoenix, Arizona; as executive vice president of the Pfizer-Serono joint venture on multiple sclerosis; and in a variety of roles at AstraZeneca and SmithKline Beecham. Before his business career, Dr. Pusey was a practicing physician at Royal Free Hospital, King George Hospital, St. Bartholomew's Hospital, and the Whittington Hospital, all based in London.
"We are pleased that Dr. Pusey has joined the company," said Mr Colin Shannon, president and CEO, PRA. "His global experience in the CRO market will be an asset to WuXiPRA. With clinical trials continuing to expand in China, having Dr. Pusey onboard will allow us to establish a stronghold in the region."
"Under James's leadership, we believe WuXiPRA will become the clinical CRO of choice in China," said Dr Ge Li, chairman and CEO, WuXi PharmaTech. "WuXi PharmaTech's local expertise and PRA's leading-edge global systems and processes will enable customers to conduct the highest-quality clinical trials in China quickly and successfully for Chinese and international regulatory filings."